Continuity, communication, and billing Communication is handled through online systems rather than in-person or on-demand clinical visits
Food and Drug Administration found that misuse reports for semaglutide were four times higher than for other GLP-1 drugs at the time
Without mechanical stimulus, the body will sacrifice lean tissue along with adipose tissue
[1] Healthcare providers should conduct a thorough assessment before initiating Zepbound, including: Detailed medical history focusing on cardiac symptoms and events Blood pressure measurement and heart rate assessment Review of current cardiovascular medications Evaluation of individual risk factors The decision to prescribe Zepbound should involve shared decision-making, weighing the potential benefits against individual risk factors
At 72 weeks, people lost an average of 15%, 19.5%, and 20.9% of their body weight on doses of 5 mg, 10 mg, and 15 mg, respectively, compared with 3.1% on placebo
Current knowledge, future clinical and translational research questions